GBA1 and Parkinson disease: We recently showed that modulation of wild-type GCase with a novel small molecule increased the enzyme activity and partially ameliorated pathological phenotypes in dopaminergic neurons from patients with GBA1-linked and non–GBA1-linked PD (13).